Podcast
Monty Pal
What it Takes to Close the Gap in Pediatric Cancer Care with Leo Wang, M.D., Ph.D.
Clips
Summary
In this episode, Leo Wang, M.D., Ph.D., pediatric oncologist, Clinical Director of the Gene Therapy Program and Director of the City of Hope Alpha Clinic, discusses the realities of caring for children with cancers that still have few effective treatments. He reflects on what it takes to begin changing those realities for patients and families.
While many childhood leukemias are now highly curable, Dr. Wang explains children with certain aggressive brain tumors still face the same outcomes they did a decade ago. This lag in progress is what drives his work today investigating CAR T‑cell therapy gene therapy in early phase clinical trials.
Throughout the conversation, Dr. Wang returns to the idea that progress in pediatric cancer care depends on collaboration across institutions, bringing together patient care, careful study and shared commitment across the research community. For him, the work centers on honoring the trust families place in the field and steadily moving discoveries from the lab to children who need more options and more time.
Related Topics
You May Also Like
Monty Pal
Podcast
Monty Pal
The Long Game of Cancer Genomics: John Carpten, Ph.D., on Building Precision Oncology that Reaches Patients
Article
Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
Podcast
MSL Talk: Tom Caravela, Josh Corriveau
MSL Career Options: The transition from Field Medical to Medical Director
Article
R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
Article
Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr